Abstract
T cells contribute to the initiation and perpetuation of autoimmunity in systemic lupus erythematosus (SLE), and seem to be directly involved in the development of related organ pathology. Defects associated with CD8+ and T-regulatory (TREG) cell function manifest in parallel with the expanded CD3+CD4−CD8− T cell lineage. The cytokine expression pattern is uniquely characterized by decreased expression of interleukin (IL)-2 and increased production of IL-17 and related cytokines. Therapeutic approaches that limit the cognate interaction between T cells and B cells, prevent inappropriate tissue homing and restore TREG cell function and the normal cytokine milieu have been entertained. Biochemical characterization of SLE T cells has revealed distinct early and late signaling aberrations, and has enabled the identification of novel molecular targets that can be corrected with small molecules, and biomarkers that may foretell disease activity and predict organ damage.
Key Points
-
Lipid raft clustering and a 'rewired' T-cell receptor lead to enhanced early signaling events in T cells from patients with systemic lupus erythematosus (SLE)
-
Signaling aberrations cause altered gene transcription and produce a unique T-cell phenotype in SLE
-
Increased numbers of CD3+CD4−CD8− T cells and interleukin (IL)-17-producing T cells, along with limited numbers of regulatory T cells, facilitate inflammation and perpetuation of autoimmunity in SLE
-
Promising therapeutic targets include the interruption of T cell–B cell cognate interactions, restoration of IL-2 production, deletion of IL-17-producing T cells, and limitation of tissue infiltration by T cells
-
Restoration of abnormally expressed signaling molecules results in the correction of effector T-cell function in vitro and may prove to be an effective and novel therapeutic approach
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Crispin, J. C. et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 181, 8761–8766 (2008).
Zhou, Y. et al. T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin. Immunol. 132, 362–370 (2009).
Shlomchik, M. J., Craft, J. E. & Mamula, M. J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 1, 147–153 (2001).
Juang, Y. T. et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest. 115, 996–1005 (2005).
Crispin, J. C., Kyttaris, V. C., Juang, Y. T. & Tsokos, G. C. How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol. 29, 110–115 (2008).
Vassilopoulos, D., Kovacs, B. & Tsokos, G. C. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J. Immunol. 155, 2269–2281 (1995).
Liossis, S. N., Ding, X. Z., Dennis, G. J. & Tsokos, G. C. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J. Clin. Invest. 101, 1448–1457 (1998).
Tsokos, G. C., Nambiar, M. P., Tenbrock, K. & Juang, Y. T. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol. 24, 259–263 (2003).
Enyedy, E. J. et al. Fcε receptor type I γ chain replaces the deficient T cell receptor ζ chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum. 44, 1114–1121 (2001).
Krishnan, S. et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J. Immunol. 181, 8145–8152 (2008).
Nambiar, M. P. et al. Forced expression of the Fc receptor γ-chain renders human T cells hyper-responsive to TCR/CD3 stimulation. J. Immunol. 170, 2871–2876 (2003).
Li, Y. et al. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J. Immunol. 178, 1938–1947 (2007).
Jury, E. C., Kabouridis, P. S., Flores-Borja, F., Mageed, R. A. & Isenberg, D. A. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J. Clin. Invest. 113, 1176–1187 (2004).
Deng, G. M. & Tsokos, G. C. Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J. Immunol. 181, 4019–4026 (2008).
Jury, E. C., Isenberg, D. A., Mauri, C. & Ehrenstein, M. R. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J. Immunol. 177, 7416–7422 (2006).
Emlen, W., Niebur, J. & Kadera, R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 152, 3685–3692 (1994).
Gergely, P. Jr et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 46, 175–190 (2002).
Gergely, P. Jr et al. Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J. Immunol. 169, 1092–1101 (2002).
Estess, P., DeGrendele, H. C., Pascual, V. & Siegelman, M. H. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J. Clin. Invest. 102, 1173–1182 (1998).
Crispin, J. C. et al. Expression of CD44v3 and CD44v6 isoforms is increased on T cells from patients with systemic lupus erythematosus and correlates with disease activity. Arthritis Rheum. doi:10.1002/art.27385.
Harley, J. B. et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40, 204–210 (2008).
Kozyrev, S. V. et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat. Genet. 40, 211–216 (2008).
Hom, G. et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM–ITGAX. N. Engl. J. Med. 358, 900–909 (2008).
Graham, R. R. et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat. Genet. 40, 1059–1061 (2008).
Kyttaris, V. C., Wang, Y., Juang, Y. T., Weinstein, A. & Tsokos, G. C. Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J. Immunol. 178, 1960–1966 (2007).
Desai-Mehta, A., Lu, L., Ramsey-Goldman, R. & Datta, S. K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 97, 2063–2073 (1996).
Tenbrock, K. & Tsokos, G. C. Transcriptional regulation of interleukin 2 in SLE T cells. Int. Rev. Immunol. 23, 333–345 (2004).
Tenbrock, K., Juang, Y. T., Gourley, M. F., Nambiar, M. P. & Tsokos, G. C. Antisense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J. Immunol. 169, 4147–4152 (2002).
Katsiari, C. G., Kyttaris, V. C., Juang, Y. T. & Tsokos, G. C. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J. Clin. Invest. 115, 3193–3204 (2005).
Kyttaris, V. C., Juang, Y. T., Tenbrock, K., Weinstein, A. & Tsokos, G. C. Cyclic adenosine 5′-monophosphate response element modulator is responsible for the decreased expression of c-Fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J. Immunol. 173, 3557–3563 (2004).
Ballestar, E., Esteller, M. & Richardson, B. C. The epigenetic face of systemic lupus erythematosus. J. Immunol. 176, 7143–7147 (2006).
Sunahori, K., Juang, Y. T. & Tsokos, G. C. Methylation status of CpG islands flanking a CAMP response element motif on the protein phosphatase 2Acα promoter determines CREB binding and activity. J. Immunol. 182, 1500–1508 (2009).
Lu, Q., Wu, A. & Richardson, B. C. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J. Immunol. 174, 6212–6219 (2005).
Lu, Q. et al. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 179, 6352–6358 (2007).
Cedeno, S. et al. Defective activity of ERK-1 and ERK-2 mitogen-activated protein kinases in peripheral blood T lymphocytes from patients with systemic lupus erythematosus: potential role of altered coupling of Ras guanine nucleotide exchange factor HSos to adapter protein Grb2 in lupus T cells. Clin. Immunol. 106, 41–49 (2003).
Mor, A., Philips, M. R. & Pillinger, M. H. The role of Ras signaling in lupus T lymphocytes: biology and pathogenesis. Clin. Immunol. 125, 215–223 (2007).
Deng, C. et al. Decreased Ras–mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum. 44, 397–407 (2001).
Gorelik, G., Fang, J. Y., Wu, A., Sawalha, A. H. & Richardson, B. Impaired T cell protein kinase Cδ activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J. Immunol. 179, 5553–5563 (2007).
Sawalha, A. H. et al. Defective T-cell ERK signaling induces interferon-regulated gene expression and overexpression of methylation-sensitive genes similar to lupus patients. Genes Immun. 9, 368–378 (2008).
Garaud, S. et al. IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J. Immunol. 182, 5623–5632 (2009).
Crispin, J. C. & Tsokos, G. C. Human TCR-αβ+ CD4− CD8− T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J. Immunol. 183, 4675–4681 (2009).
Blanco, P. et al. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 52, 201–211 (2005).
Viallard, J. F. et al. HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 125, 485–491 (2001).
Couzi, L. et al. Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis. Arthritis Rheum. 56, 2362–2370 (2007).
Stohl, W. Impaired polyclonal T cell cytolytic activity. A possible risk factor for systemic lupus erythematosus. Arthritis Rheum. 38, 506–516 (1995).
Dean, G. S., Anand, A., Blofeld, A., Isenberg, D. A. & Lydyard, P. M. Characterization of CD3+ CD4− CD8− (double negative) T cells in patients with systemic lupus erythematosus: production of IL-4. Lupus 11, 501–507 (2002).
Mehal, W. Z. & Crispe, I. N. TCR ligation on CD8+ T cells creates double-negative cells in vivo. J. Immunol. 161, 1686–1693 (1998).
Anand, A., Dean, G. S., Quereshi, K., Isenberg, D. A. & Lydyard, P. M. Characterization of CD3+ CD4− CD8− (double negative) T cells in patients with systemic lupus erythematosus: activation markers. Lupus 11, 493–500 (2002).
Shivakumar, S., Tsokos, G. C. & Datta, S. K. T cell receptor α/β expressing double-negative (CD4−/CD8−) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J. Immunol. 143, 103–112 (1989).
Sieling, P. A. et al. Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J. Immunol. 165, 5338–5344 (2000).
Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V. K. IL-17 and TH17 cells. Annu. Rev. Immunol. 27, 485–517 (2009).
Yang, J. et al. TH17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 60, 1472–1483 (2009).
Zhang, Z., Kyttaris, V. C. & Tsokos, G. C. The role of IL-23/IL-17 axis in lupus nephritis. J. Immunol. 183, 3160–3169 (2009).
Kang, H. K., Liu, M. & Datta, S. K. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory TH17 cells. J. Immunol. 178, 7849–7858 (2007).
Doreau, A. et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat. Immunol. 10, 778–785 (2009).
Steinmetz, O. M. et al. CXCR3 mediates renal TH1 and TH17 immune response in murine lupus nephritis. J. Immunol. 183, 4693–4704 (2009).
Wang, Y. et al. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin. Exp. Immunol. 159, 1–10 (2009).
Hsu, H. C. et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 9, 166–175 (2008).
Awasthi, A. & Kuchroo, V. K. Immunology. The yin and yang of follicular helper T cells. Science 325, 953–955 (2009).
Simpson, N. et al. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum. 62, 234–244 (2010).
Bubier, J. A. et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc. Natl Acad. Sci. USA 106, 1518–1523 (2009).
Linterman, M. A. et al. Follicular helper T cells are required for systemic autoimmunity. J. Exp. Med. 206, 561–576 (2009).
Odegard, J. M. et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J. Exp. Med. 205, 2873–2886 (2008).
Wong, C. K. et al. Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J. Clin. Immunol. 30, 45–52 (2010).
Feuerer, M., Hill, J. A., Mathis, D. & Benoist, C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat. Immunol. 10, 689–695 (2009).
Crispin, J. C., Martinez, A. & Alcocer-Varela, J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 21, 273–276 (2003).
Miyara, M. et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol. 175, 8392–8400 (2005).
Lee, J. H. et al. Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 117, 280–286 (2006).
Valencia, X., Yarboro, C., Illei, G. & Lipsky, P. E. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 178, 2579–2588 (2007).
Bonelli, M. et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int. Immunol. 20, 861–868 (2008).
Vargas-Rojas, M. I., Crispin, J. C., Richaud-Patin, Y. & Alcocer-Varela, J. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 17, 289–294 (2008).
Alcocer-Varela, J. & Alarcon-Segovia, D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J. Clin. Invest. 69, 1388–1392 (1982).
Yu, A., Zhu, L., Altman, N. H. & Malek, T. R. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30, 204–217 (2009).
Linker-Israeli, M. et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 147, 117–123 (1991).
Wan, S., Xia, C. & Morel, L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J. Immunol. 178, 271–279 (2007).
Iikuni, N., Lourenco, E. V., Hahn, B. H. & La Cava, A. Cutting Edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus. J. Immunol. 183, 1518–1522 (2009).
Dai, Z. et al. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J. Exp. Med. 206, 793–805 (2009).
Zhang, L., Bertucci, A. M., Ramsey-Goldman, R., Burt, R. K. & Datta, S. K. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-β-producing CD8+ Treg cells are associated with immunological remission of lupus. J. Immunol. 183, 6346–6358 (2009).
Finck, B. K., Linsley, P. S. & Wofsy, D. Treatment of murine lupus with CTLA4Ig. Science 265, 1225–1227 (1994).
Daikh, D. I. & Wofsy, D. Cutting Edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166, 2913–2916 (2001).
Kalled, S. L., Cutler, A. H., Datta, S. K. & Thomas, D. W. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J. Immunol. 160, 2158–2165 (1998).
Daikh, D. I., Finck, B. K., Linsley, P. S., Hollenbaugh, D. & Wofsy, D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/Gp39 costimulation pathways. J. Immunol. 159, 3104–3108 (1997).
Early, G. S., Zhao, W. & Burns, C. M. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand Black × New Zealand White mice. Response correlates with the absence of an anti-antibody response. J. Immunol. 157, 3159–3164 (1996).
Sidiropoulos, P. I. & Boumpas, D. T. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13, 391–397 (2004).
Boumpas, D. T. et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719–727 (2003).
Kalunian, K. C., Davis, J. C. Jr, Merrill, J. T., Totoritis, M. C. & Wofsy, D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 3251–3258 (2002).
Iwai, H. et al. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J. Immunol. 171, 2848–2854 (2003).
Iwai, H. et al. Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J. Immunol. 169, 4332–4339 (2002).
Hu, Y. L., Metz, D. P., Chung, J., Siu, G. & Zhang, M. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J. Immunol. 182, 1421–1428 (2009).
Usmani, N. & Goodfield, M. Efalizumab in the treatment of discoid lupus erythematosus. Arch. Dermatol. 143, 873–877 (2007).
Naka, T., Nishimoto, N. & Kishimoto, T. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 4 (Suppl. 3), S233–S242 (2002).
Finck, B. K., Chan, B. & Wofsy, D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest. 94, 585–591 (1994).
Mihara, M., Takagi, N., Takeda, Y. & Ohsugi, Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin. Exp. Immunol. 112, 397–402 (1998).
Tsai, C. Y., Wu, T. H., Yu, C. L., Lu, J. Y. & Tsai, Y. Y. Increased excretions of β2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm–Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85, 207–214 (2000).
Fukatsu, A. et al. Distribution of interleukin-6 in normal and diseased human kidney. Lab. Invest. 65, 61–66 (1991).
Illei, G. G. et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 62, 542–552 (2010).
Kyttaris, V. C., Zhang, Z., Kuchroo, V. K., Oukka, M. & Tsokos, G. C. Cutting Edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J. Immunol. doi:10.4049/jimmunol.0903595.
Wu, H. Y., Quintana, F. J. & Weiner, H. L. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+. J. Immunol. 181, 6038–6050 (2008).
Weinblatt, M. E. et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 58, 3309–3318 (2008).
Bahjat, F. R. et al. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 58, 1433–1444 (2008).
Deng, G. M., Liu, L., Bahjat, R., Pine, P. R. & Tsokos, G. C. Inhibition of spleen tyrosine kinase suppresses skin and kidney disease in lupus prone mice. Arthritis Rheum. doi:10.1002/art.27452.
Cardenas, M. E., Zhu, D. & Heitman, J. Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin. Curr. Opin. Nephrol. Hypertens. 4, 472–477 (1995).
Fernandez, D. R. et al. Activation of mammalian target of rapamycin controls the loss of TCRζ in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J. Immunol. 182, 2063–2073 (2009).
Lui, S. L. et al. Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. Nephrol. Dial. Transplant. 23, 2768–2776 (2008).
Fernandez, D., Bonilla, E., Mirza, N., Niland, B. & Perl, A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2983–2988 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Crispín, J., Kyttaris, V., Terhorst, C. et al. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 6, 317–325 (2010). https://doi.org/10.1038/nrrheum.2010.60
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.60
This article is cited by
-
A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus: study from two Japanese tertiary referral centers
Arthritis Research & Therapy (2024)
-
CircPTPN22 modulates T-cell activation by sponging miR-4689 to regulate S1PR1 expression in patients with systemic lupus erythematosus
Arthritis Research & Therapy (2023)
-
Lymphocyte subset clustering analysis in treatment-naive patients with systemic lupus erythematosus
Clinical Rheumatology (2021)
-
Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients
Nature Communications (2019)
-
Polydatin effectively attenuates disease activity in lupus-prone mouse models by blocking ROS-mediated NET formation
Arthritis Research & Therapy (2018)